source
- Arcus kidney cancer drug shows stronger potency than Merck's Welireg, boosting sharesArcus Biosciences reported follow‑up data from its late‑stage kidney cancer trial that suggest its experimental therapy, casdatifan, may be more potent than Merck's approved drug Welireg. Analysts…
- AstraZeneca partners with Oracle to boost clinical trial patient recruitment using AIAstraZeneca announced a collaboration with data-technology firm Oracle to apply artificial-intelligence tools to clinical-trial recruitment. The non-binding agreement will let the partners explore…